Paolo Tarantino: Can we get rid of the anthracyclines from the KN522 regimen?

Paolo Tarantino, Researcher at the European Institute of Oncology and clinical research fellow at the Dana-Farber Cancer Institute, shared a post on X/Twitter:

“Can we get rid of the anthracyclines from the KN522 regimen? The ph2 NeoPACT trial is published on JAMA Oncology: neoadjuvant Carbo/Docetaxel/Pembro x6 led to a pCR rate of 58% and 3y EFS of 86% for stage I-III TNBC. Confirmatory phase 3 SCARLET trial ongoing.”

For the article click here.
Source: Paolo Tarantino/Twitter